This is a Phase 1 randomized, placebo-controlled, modified double-blinded clinical trial designed to evaluate the safety and immunogenicity of a HIV vaccine called FLSC (full-length single chain) in healthy volunteers without HIV infection. This novel vaccine was developed by investigators at the Institute of Human Virology as a potential future strategy to help prevent HIV infection.
Volunteers must be:
- 18-45 years of age,
- HIV negative,
- and have never previously participated in an HIV or DNA vaccine trial.
Compensation will be given for travel and expenses.